Results 221 to 230 of about 7,676,849 (387)

Poster 210 successful outcome of a pediatric patient with eastern equine encephalitis, despite a high morbidity and mortality rate associated with the disease: A case report. Clinton Faulk, MD (Pitt County Mem Hosp, Greenville, NC); Billy Smith, MD; Daniel Moore, MD, e-mail: cjmfaulk@yahoo.com [PDF]

, 2004

openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Comparison of clinician- and patient-reported outcome measures in 95 abdominoplasty cases using BODY-Q and MCCRO-Q

JPRAS Open
/Summary: Patient-reported outcome measures (PROMs) and clinician-reported outcome measures (CROMs) are not routinely compared and they could be used to assess outcomes and aid patient selection and informed consent.Between July 2016 and February 2020 ...
Samuel Thomas Kitching, Claudia Rocco, Rachel Harwood, Gary Ross   +3 more
doaj  

Clinical events and patient-reported outcome measures in peritoneal dialysis. [PDF]

BMC Nephrol
Malaweera A, Huang LL, McMahon LP.
europepmc   +1 more source

MS4 THE IMPACT OF HEALTH CARE ATTITUDES ON PATIENT REPORTED OUTCOMES (PRO'S)

, 2003
SC Bolge, K. Annunziata, JA Donohue
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

Patient-Reported Outcome Measures (PROMS) in Lymphoma. [PDF]

Curr Oncol
Akkad N, Flowers CR.
europepmc   +1 more source

PHP37 USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING

, 2003
Mary Edmondson, Diana D. McDonnell
openalex   +1 more source

An acute problem? A report of the National Confidential Enquiry into Patient Outcome and Death [PDF]

, 2005
Sheila Adam, Mandy Odell
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source